The cancer startup develops novel immunotherapies that target the immune-suppressive tumor microenvironment to attack cancer. The company is developing immuno-oncology drugs which could be combined with existing immunotherapies to enhance the efficiency of detecting and killing cancer cells.
Genprex raised $6.4 million in IPO at a share price of $5.
Unlike most of the commercial blockbuster lung cancer immunotherapies, its unique lead candidate, Oncoprex® targets advanced lung cancer treatment.
Gene therapy company, Sangamo Therapeutics collaborated with Gilead Sciences subsidiary, Kite Pharma to develop next-generation ex vivo (out of the ...
Novartis’ nuclear medicine subsidiary, Advanced Accelerator Applications (AAA) inked a global partnership with US-based Cancer Targeted Technology (CTT) for the ...
KEY POINTS Lorlatinib is a next-generation ALK/ROS1 tyrosine kinase inhibitor. Last year, lorlatinib had received Breakthrough Therapy designation from the ...
Rare diseases company, Amicus Therapeutics’ New Drug Application (NDA) for migalastat (migalastat HCl), for filing under priority review is accepted ...